2,127 research outputs found
Kuo šeimos mediacija gali būti naudinga?
No full textVDU Tėvų akademija – tai dalis Socialinių mokslų fakulteto misijos. Kartą per mėnesį dovanojami nemokami užsiėmimai tėvams, siekiant prisidėti prie visuomenės tobulėjimo.
2023 m. lapkričio 30 d. vyko VDU Tėvų akademijos nuotolinė paskaita „Kuo šeimos mediacija gali būti naudinga?“.
Nors mediacijos sąvoką visuomenėje girdime dažnai, tačiau vis dar nemažai painiavos kyla kalbant apie jos paskirtį ir kuo ji gali būti naudinga. Paskaitoje buvo supažindinta, kuo mediacija skiriasi nuo kitų šeimai skirtų paslaugų, kada galima mediacija, kokius konfliktus ji gali padėti spręsti ir kodėl reikėtų rinktis mediaciją?
Paskaitą vedė dr. Živilė Kėrytė, Šeimos santykių instituto šeimos mediatorė, sociologė, projektų vadovė
Ar istorija pasmerkta skaldyti, o gal atvirkščiai – gali suvienyti? Atminties vaidmuo formuojant tarptautinius santykius Vidurio Europoje
No full textPagrindinis tyrimo klausimas – ar istorija pasmerkta skaldyti, o gal atvirkščiai – gali suvienyti? Autorius teigia, kad, viena vertus, tiesos sąvokos atsisakymas istoriografijoje gali paskatinti istoriją traktuoti kaip selektyvių argumentų rezervuarą politinėse kovose. Šia prasme istorija visada skaldys. Kita vertus, tiesa gali būti pasiekta. Mokslininkai turi kelis būdus patikrinti, kiek toli nuo tiesos yra teiginys apie istoriją. Egzistuoja šešios pagrindinės tikrinimo taisyklės, kurios aptariamos straipsnyje. Nagrinėjama nacionalinio tapatumo samprata, kultūra, suvokiama kaip nacionalinio tapatumo pagrindas, ir regioninio bendradarbiavimo kontekstas.The main research question is whether history is doomed to divide or whether it may unite. The author argues that, on the one hand, the rejection of the concept of truth in historiography may lead to treating history as a reservoir of selective argument in political struggles. In this sense, history will always divide. However, on the other hand, truth may be achieved. Scholars have several ways to test how far from the truth is a statement concerning history. There are six basic rules to test it, which are discussed in the article. The concept of national identity, culture perceived as the backbone of national identity and the regional cooperation context are examined
The Perception of Pelvic Floor Muscle Function amongst Exercising Women Who Are Repeatedly Instructed to Contract Their Pelvic Floor Muscles
No full textIn this study, the self-perception of pelvic floor muscle (PFM) contractions amongst women receiving repeated verbal instructions during exercise classes was examined. The prevalence and severity of urinary stress incontinence were also assessed. This cross-sectional observational study included 46 women (mean age 48 (±8.6)), who regularly participated in Pilates classes where repeated instruction was given to contract PFM (“instruction group”; N = 22) or not (controls, N = 24). PFM function was evaluated using transabdominal ultrasound. Simultaneously, the participant described her personal evaluation of her PFM contraction ability. The International Consultation on Incontinence Questionnaire–Short Form was also utilized. Most women (80%) correctly contract PFM; however, 95% did not perform a voluntary contraction during leg movement, without differences observed between groups. A higher perception of PFM contraction was found in the “instruction group” when performing knee flexion towards the chest without specific verbal instruction. Women who were instructed to contract their PFM suffered less incontinence and had a lower degree of severity than the controls. Most women performing Pilates exercises correctly contracted their PFM. However, there was no PFM voluntary contraction during leg movement. Exposure to repeated verbal instructions to contract PFM, over time, might lead to an improvement in women’s perception of their ability to contract PFM. Verbal instructions for PFM contraction were found to be effective in reducing urinary incontinence
Physician referrals of patients with neck and low back pain for physical therapy in outpatient clinics: a cross-sectional study
No full textAbstract Background Patients commonly seek outpatient physical therapy services for musculoskeletal disorders. Understanding these patient groups in Israel provides valuable insights into the healthcare system. We aimed to investigate physician referral patterns for physical therapy across different age and sex groups, focusing on neck and low back pain. Additionally, we sought to explore the therapeutic interventions provided by physical therapists for these conditions. Methods For this retrospective, cross-sectional study we utilized data from a national health maintenance organization covering > 4 million people at 100 physical therapy outpatient clinics. We measured the prevalence rates of physicians’ referral patterns for neck and low back pain according to age and sex, as well as therapeutic interventions prescribed by physical therapists. We used Z-tests to assess the differences in prevalence rates between women and men within the same age group. Logistic regression analyses were used to evaluate the likelihood of patients of a specific age group being referred to physical therapy compared with the total sample. We analyzed prevalence rates of different treatment protocols used by physical therapists according to these referrals. Results Overall, 1,593,592 physician referrals for physical therapy were made over 6 years for all musculoskeletal conditions. Of those, 32.4% were for spine disorders, with 21.2% for low back pain and 11.1% for neck pain, mostly chronic (80.6% and 72.7%, respectively). Women were more likely than men to be referred for both low back pain (odds ratio = 1.36, 95% confidence interval = 1.34–1.38, p < 0.001) and neck pain (1.40, 1.37–1.43, p < 0.001). All referral rates increased with age. The most common treatment provided by physical therapists for neck and low back pain was education and advice for an active lifestyle. Conclusions This study provides comprehensive data that highlight significant trends related to age, acuteness, and sex. Chronic low back and neck pain are the predominant reasons for physical therapy referrals, particularly among women and older adults. Physician referrals for neck and low back pain aligned with the epidemiology of such conditions in the Israeli population, underscoring the need for targeted rehabilitation strategies, early intervention programs, and effective healthcare service planning
Thymoquinone: Fifty years of success in the battle against cancer models
No full textThymoquinone (TQ), the main active constituent of black seed essential oil, exhibits promising effects against inflammatory diseases and cancer. TQ, modulates signaling pathways that are key to cancer progression, and enhances the anticancer potential of clinical drugs while reducing their toxic side effects. Considering that TQ was isolated 50 years ago, this review focuses on TQ's chemical and pharmacological properties and the latest advances in TQ analog design and nanoformulation. We discuss our current state of knowledge of TQ's adjuvant potential and in vivo antitumor activity and highlight its ability to modulate the hallmarks of cancer. © 2013 Elsevier Ltd. All rights reserved.Abusnina A, 2011, CELL SIGNAL, V23, P152, DOI 10.1016-j.cellsig.2010.08.015; Akhondian J, 2011, EPILEPSY RES, V93, P39, DOI 10.1016-j.eplepsyres.2010.10.010; Al-Ali Amein, 2008, J Ayub Med Coll Abbottabad, V20, P25; Alam S, 2012, INT J NANOMED, V7, P5705, DOI 10.2147-IJN.S35329; Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107; Alenzi FQ, 2010, BRIT J BIOMED SCI, V67, P20; Alhosin M, 2012, INVEST NEW DRUG, V30, P1813, DOI 10.1007-s10637-011-9734-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016-j.bcp.2009.12.015; Al-Johar D, 2008, PHYTOTHER RES, V22, P1311, DOI 10.1002-ptr.2487; Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193; Arafa ESA, 2011, MUTAT RES-FUND MOL M, V706, P28, DOI 10.1016-j.mrfmmm.2010.10.007; Badary OA, 2001, CANCER DETECT PREV, V25, P362; Badary OA, 1999, J ETHNOPHARMACOL, V67, P135, DOI 10.1016-S0378-8741(98)00242-6; Badary OA, 1999, EUR J CANCER PREV, V8, P435, DOI 10.1097-00008469-199910000-00009; Badary OA, 2000, TOXICOLOGY, V143, P219, DOI 10.1016-S0300-483X(99)00179-1; Badr G, 2011, PLOS ONE, V6, DOI 10.1371-journal.pone.0023741; Banerjee S, 2010, NUTR CANCER, V62, P938, DOI 10.1080-01635581.2010.509832; Banerjee S, 2010, PHARM RES-DORDR, V27, P1146, DOI 10.1007-s11095-010-0145-3; Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158-0008-5472.CAN-08-4235; Basarslan F, 2012, HUM EXP TOXICOL, V31, P726, DOI 10.1177-0960327111433185; Brewer J, 2006, BIOMED SCI INSTRUM, V42, P37; Chehl N, 2009, HPB, V11, P373, DOI 10.1111-j.1477-2574.2009.00059.x; CREMER D, 1987, J MED CHEM, V30, P1678, DOI 10.1021-jm00392a027; Daba MH, 1998, TOXICOL LETT, V95, P23, DOI 10.1016-S0378-4274(98)00012-5; Das S, 2012, PLOS ONE, V7, DOI 10.1371-journal.pone.0046641; Dergarabetian Eileen Manasse, 2013, Front Biosci (Elite Ed), V5, P706; Effenberger K, 2010, CHEM BIODIVERS, V7, P129, DOI 10.1002-cbdv.200900328; Effenberger-Neidnicht K, 2011, CHEMBIOCHEM, V12, P1237, DOI 10.1002-cbic.201000762; El-Dakhakhny M., 1963, PLANTA MED, V11, P465; El-Dakhakhny M, 2002, J ETHNOPHARMACOL, V81, P161, DOI 10.1016-S0378-8741(02)00051-X; El Gazzar MA, 2007, BBA-GEN SUBJECTS, V1770, P556, DOI 10.1016-j.bbagen.2007.01.002; El-Mahdy MA, 2005, INT J CANCER, V117, P409, DOI 10.1002-ijc.21205; El Mezayen R, 2006, IMMUNOL LETT, V106, P72, DOI 10.1016-j.imlet.2006.04.012; El-Najjar N, 2010, APOPTOSIS, V15, P183, DOI 10.1007-s10495-009-0421-z; El-Najjar Nahed, 2011, J Chem Biol, V4, P97, DOI 10.1007-s12154-010-0052-4; Farah Nourelhoda, 2005, V41, P211; Fouda AMM, 2008, BASIC CLIN PHARMACOL, V103, P109, DOI 10.1111-j.1742-7843.2008.00260.x; Gali-Muhtasib H, 2008, J CELL MOL MED, V12, P330, DOI 10.1111-j.1582-4934.2007.00095.x; Gali-Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016-j.biocel.2005.10.009; Gali-Muhtasib H, 2008, CANCER RES, V68, P5609, DOI 10.1158-0008-5472.CAN-08-0884; Gali-Muhtasib H, 2004, INT J ONCOL, V25, P857; Gali-Muhtasib HU, 2004, ANTI-CANCER DRUG, V15, P389, DOI 10.1097-01.cad.0000125054.43188.56; Ganea GM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088-0957-4484-21-28-285104; Gohari AR, 2012, SCI WORLD J, DOI 10.1100-2012-203861; Gokce A, 2011, HUM EXP TOXICOL, V30, P897, DOI 10.1177-0960327110382564; Grosso C, 2010, J SEP SCI, V33, P2211, DOI 10.1002-jssc.201000192; Gupta V.K., 2010, INT J RES PHARM SCI, V1, P163; Gurung R.L., 2010, PLOS ONE, V5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016-j.cell.2011.02.013; Harzallah HJ, 2012, OXID MED CELL LONGEV, DOI 10.1155-2012-854065; Hussain AR, 2011, FREE RADICAL BIO MED, V50, P978, DOI 10.1016-j.freeradbiomed.2010.12.034; Hussain J, 2010, NAT PROD COMMUN, V5, P1785; Ivankovic S., 2006, Experimental Oncology, V28, P220; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186-1756-9966-29-87; Kanter M, 2005, WORLD J GASTROENTERO, V11, P6662; Kanter M, 2008, NEUROCHEM RES, V33, P579, DOI 10.1007-s11064-007-9481-z; Kanter M, 2011, TOXICOL IND HEALTH, V27, P387, DOI 10.1177-0748233710387630; Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158-0008-5472.CAN-07-1483; Koka PS, 2010, EXP BIOL MED, V235, P751, DOI 10.1258-ebm.2010.009369; Kolli-Bouhafs K, 2012, INVEST NEW DRUG, V30, P2121, DOI 10.1007-s10637-011-9777-3; Lei XF, 2012, DIGEST DIS SCI, V57, P2296, DOI 10.1007-s10620-012-2156-x; Li F, 2010, BRIT J PHARMACOL, V161, P541, DOI 10.1111-j.1476-5381.2010.00874.x; Lukas B, 2009, J AGR FOOD CHEM, V57, P1362, DOI 10.1021-jf802963h; Mansour MA, 2000, LIFE SCI, V66, P2583, DOI 10.1016-S0024-3205(00)00592-0; Manter DK, 2007, J CHEM ECOL, V33, P2133, DOI 10.1007-s10886-007-9368-0; Martin TM, 2006, BIOMED SCI INSTRUM, V42, P332; Mu Hai-qi, 2012, Zhonghua Yi Xue Za Zhi, V92, P392; Nagi MN, 2011, J BIOCHEM MOL TOXIC, V25, P135, DOI 10.1002-jbt.20369; Nagi MN, 2000, PHARMACOL RES, V41, P283, DOI 10.1006-phrs.1999.0585; Nagi MN, 2010, FOOD CHEM TOXICOL, V48, P2361, DOI 10.1016-j.fct.2010.05.072; Ng WK, 2011, TOXICOL IN VITRO, V25, P1392, DOI 10.1016-j.tiv.2011.04.030; Nili-Ahmadabadi A, 2011, DARU, V19, P282; Norwood AA, 2006, BIOMED SCI INSTRUM, V42, P350; Odeh F, 2012, DRUG DELIV, V19, P371, DOI 10.3109-10717544.2012.727500; Paramasivam A, 2012, TOXICOL LETT, V213, P151, DOI 10.1016-j.toxlet.2012.06.011; Pathan SA, 2011, BIOMED CHROMATOGR, V25, P613, DOI 10.1002-bmc.1492; Ravindran J, 2010, BIOCHEM PHARMACOL, V79, P1640, DOI 10.1016-j.bcp.2010.01.023; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016-j.chembiol.2008.03.013; Richards LR, 2007, BIOMED SCI INSTRUM, V43, P242; Roepke M, 2007, CANCER BIOL THER, V6, P160; Rooney S, 2005, ANTICANCER RES, V25, P4255; Ross Richards L, 2009, BIOMED SCI INSTRUM, V45, P268; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016-j.intimp.2005.06.008; Sayed-Ahmed MM, 2007, CLIN EXP PHARMACOL P, V34, P399, DOI 10.1111-j.1440-1681.2007.04560.x; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158-1541-7786.MCR-07-2088; Shah M, 2010, INT J PHARMACEUT, V400, P165, DOI 10.1016-j.ijpharm.2010.08.008; Shah M, 2011, J NANOSCI NANOTECHNO, V11, P5702, DOI 10.1166-jnn.2011.4493; Singh A, 2013, COLLOID SURFACE B, V102, P822, DOI 10.1016-j.colsurfb.2012.08.038; Suddek GM, 2013, INFLAMMOPHARMACOLOGY, V21, P427, DOI 10.1007-s10787-012-0160-6; Sutton KM, 2012, BIOCHEM BIOPH RES CO, V426, P421, DOI 10.1016-j.bbrc.2012.08.111; Tan M, 2006, BIOMED SCI INSTRUM, V42, P363; Torres MP, 2010, MOL CANCER THER, V9, P1419, DOI 10.1158-1535-7163.MCT-10-0075; TRANG NTD, 1993, PLANTA MED, V59, P99, DOI 10.1055-s-2006-959619; Ulu R, 2012, FOOD CHEM TOXICOL, V50, P1675, DOI 10.1016-j.fct.2012.02.082; Velho-Pereira R, 2011, CELL BIOL INT, V35, P1025, DOI 10.1042-CBI20100701; Wang Yong-Mei, 2011, Zhonghua Yi Xue Za Zhi, V91, P3111; Wilson-Simpson F, 2007, BIOMED SCI INSTRUM, V43, P378; Woo CC, 2011, BIOCHEM PHARMACOL, V82, P464, DOI 10.1016-j.bcp.2011.05.030; Woo CC, 2012, BIOCHEM PHARMACOL, V83, P443, DOI 10.1016-j.bcp.2011.09.029; Worthen DR, 1998, ANTICANCER RES, V18, P1527; Wu Zhi-hao, 2011, Yaoxue Xuebao, V46, P910; Yi TF, 2008, MOL CANCER THER, V7, P1789, DOI 10.1158-1535-7163.MCT-08-0124; Yin Z, 2013, ACS CHEM BIOL, V8, P303, DOI 10.1021-cb3004379; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016-j.ajpath.2011.06.031; Zafeer MF, 2012, J BIOCHEM MOL TOXIC, V26, P199, DOI 10.1002-jbt.2140268
Herojus, kokio dar nebuvo : recenzija
No full textStraipsnyje, kuris skirtas rašytojo, 2004 m. Nacionalinės premijos laureato Sigito Parulskio keturiasdešimtmečiui, nagrinėjamas jo romanų, esė ir eilėraščių tragikomiškasis herojus. Straipsnio autorės manymu, tokio tragikomiško herojaus, koks būdingas Parulskio kūrybai, lietuvių literatūroje dar nebuvo. Jis nesąs labai simpatiškas personažas, tačiau turi tiek mūsų laikų (ir postmodernių, ir posovietinių) žmogui būdingų savybių, kad nejučiom imama identifikuotis su jo "aš". Šis personažas išgyvena viską, kas gali nutikti žmogui, neturinčiam jokių išankstinių priešiškumo ar savisaugos nuostatų. Jis nekovoja ir už gėrį, grožį ir tiesą, bet nėra ir bestuburis, -- stebi ir diagnozuoja aplinkinius ir save. Tik ironiškame santykyje su tikrove atsiskleidžiąs jo ypatingumas: įsiklausymas į menkiausius žmoniškumo, Dievo ir meilės galimybės ženklus. Tai, straipsnio autorės nuomone, ir tampa didžiuoju jo išteisinimu kelionėje per gyvenimo pragarus, kur negalima likti nekaltam, nesužeistam ir nesužeisti kitų. Straipsnio autorė negaili komplimentų Parulskio talentui: jos manymu, rašytojas turi tragikomiškajai tikrovės pusei atpažinti reikalingą meninę klausą ir poeto talentą, nes lyg iš atsitiktinių gyvenimo nuotrupų savo esė sugeba atskleisti daugeliui atpažįstamo tipiško individo likimą. Straipsnio autorės nuomone, Parulskis kuria tragikomišką herojų, kuris nebijo ironizuoti mūsų laikų tikrovės ir jos vertybių. Tačiau lietuvių literatūrai vis dėlto dar vis trūkstą Don Kichoto -- tragikomiško herojaus, kuris kovoja dėl amžinų vertybių, ir, nors visi juokiasi iš jo, jis tos pajuokos nebijo. Reikšminiai žodžiai: Sigitas Parulskis; Kūryba; Interpretacija; Sigitas Parulskis; Creation; InterpretationThe article, dedicated to the forty years anniversary of writer Sigitas Parulskis, a winner of the National Prize 2004, examines the tragicomic characters of his novels, essays and poems. In the opinion of the author of the article, previously there had not been such a tragicomic character, as the one, found in Parulskis’s work, in Lithuanian literature. The character is not quite prepossessing, however he has the traits, characteristic of a person of our times (both postmodern and post-Soviet) that the reader cannot help but identify with his “ego”. The character experiences everything, which can happen to a person, who does not have any hostile prejudice or self-preservation. He does not fight for the good, beauty or truth, but he also is not spineless – he observes and analyzes the people around him and himself. His peculiarity is revealed only in the ironic relation with reality: his ear to the tiniest signs of humanity, God and possibilities of love, which, in the opinion of the author of the article, becomes his biggest justification in his travel through the hell of life, where one cannot remain innocent, not hurt or avoid to hurt others. The author of the article does not spare compliments to Parulskis’s talents: in her opinion, the writer has the artistic ear for recognition of the tragicomic side of reality and the talent of a poet, since in his essays he is able to reveal the fate of a typical individual, recognizable to many from random fragments of life. In the opinion of the author of the article Parulskis develops a tragicomic character, who is not afraid to view the reality of our times and its values with irony, however Lithuanian literature still lacks a Don Quixotes figure, i. e. a tragicomic character, who fights for eternal values and is not afraid of others laughing at him
Kaip universiteto studijų aplinka gali ugdyti studentų kūrybiškumą? Lietuvos studentų požiūriai
No full textStudents’ creativity has been increasingly researched in higher education. Until recently,
however, empirical studies investigating students’ views of how universities can contribute to the
development of their creativity have been rare. The present study aims to investigate how university
learning environment can contribute to undergraduate philology students’ creativity as seen by the
students themselves. The data were collected through questionnaires and analysed using qualitative
research method of content analysis.
The general conclusion of this study is that the study participants consider that universities can
foster their students’ creativity in some ways. Firstly, they think that university curriculum should
contain assignments aimed at developing student creativity. Prominent among the findings was the
students’ belief that their university teachers are important contributors to this process. Besides, the
students considered that their creativity can be developed by introducing a special study subject,
by enhancing their transferable skills, and that more collaborative learning and special university
events could make an impact on their creativity. On the other hand, the results of the present study
have also revealed some challenges that call for further research.Studentų kūrybiškumo ugdymo aukštajame moksle tematika jau sulaukė didelio
užsienio tyrėjų dėmesio, tačiau Lietuvoje dar pasigendama empirinių tyrimų, analizuojančių
studentų požiūrius, kaip universiteto studijų aplinka gali prisidėti prie
jų kūrybiškumo ugdymo. Šiuo tyrimu siekiama nustatyti filologijos bakalauro studijų
studentų požiūrius, kaip universiteto studijų aplinka gali plėtoti jų kūrybiškumą.
Tyrimo duomenys buvo gauti anketinės apklausos būdu ir išanalizuoti taikant kokybinio
tyrimo turinio analizės metodą.
Tyrimo rezultatai rodo, kad, studentų požiūriu, jų universitetai yra ta mokymosi
aplinka, kuri yra palanki studentų kūrybiškumui plėtoti. Svarbu tai, kad tyrimo dalyviai
aiškiai įvardijo būdus, kaip tai gali būti įgyvendinta. Pirma, studentai nurodė,
kad didesnio skaičiaus kūrybiškumą skatinančių užduočių įtraukimas į universitetų
studijų programas turėtų teigiamą poveikį jų asmeniniam kūrybiškumui. Svarbus
šio tyrimo rezultatas – dalies studentų išreikštas požiūris į universiteto dėstytojų vaidmenį
šiame procese, t. y. dalis studentų nurodė, kad dėstytojai, būdami integralia
universiteto studijų aplinkos dalimi, gali reikšmingai prisidėti prie jų kūrybiškumo
ugdymo. Be to, tyrimo metu nustatyti ir kiti būdai, kurie, studentų nuomone, turėtų
teigiamą įtaką studentų kūrybiškumo plėtotei, t. y. specialiai tam skirtas universiteto
studijų dalykas, studentų keliamųjų gebėjimų ugdymas, mokymosi bendradarbiaujant
skatinimas ir specialūs universitete organizuojami renginiai. Kita vertus, šio tyrimo
rezultatai taip pat atskleidė studentų kūrybiškumui ugdyti kylančius iššūkius
Aplicación, reestructuración y nueva baremación de la prueba de comprensión lectora de Alexandre Gali, para los niños de 7, 8 y 9 años, que cursan el ciclo inicial y medio en los CP de Barcelona ciudad
No full textDar una visión de la opinión sobre la comprensión lectora de algunos autores. Reestructurar y dar una nueva baremación de la prueba de comprensión lectora de Alexandre Gali. Verificar que las cuatro pruebas de comprensión lectora de A.G. son similares. Comparar el rendimiento en comprensión lectora entre catalanoparlantes y castellanoparlantes. La muestra de la primera aplicación de las pruebas de comprensión lectora de A. Gali está compuesta por uno de los centros escolares públicos de Barcelona ciudad, elegido al azar, en donde se imparte la enseñanza en catalán desde hace 3 años. La prueba se aplica a todos los niños de 7, 8 y 9 años de edad que durante el curso 81-82 estén cursando el ciclo inicial y medio de EGB en el centro elegido (suman un total de 136 sujetos). La muestra de la aplicación de la prueba experimental está compuesta por 281 sujetos de las restantes escuelas que imparten la enseñanza en catalán desde hace 3 años. Planteamiento del problema de la comprensión lectora: concepto, etapas del proceso lector, madurez lectora, factores, desarrollo, descripción de la prueba de comprensión lectora de A. Gali. Aplicación de las pruebas de comprensión lectora de A. Gali. Análisis estadístico. Reestructuración de la prueba. Aplica la prueba experimental. Análisis estadístico. Expone baremos y conclusiones. En la prueba de A. Gali se han estudiado las siguientes variables: sexo, edad, lengua familiar de los niños, preescolarización y clase socio-económica familiar. En la prueba experimental se estudia: la edad, la lengua familiar, la preescolarización, la clase socio-económica familiar y los métodos de aprendizaje lector. Prueba de comprensión lectora de Alexandre Gali. Prueba experimental de comprensión lectora. Calificaciones de evaluación. Kolmogorov, correlación, comparación de medias, U de Mann-Whitney, fiabilidad y validez. Sería interesante una posterior reestructuracion de las pruebas, se debería actualizar el lenguaje y adaptar algunos contenidos al nivel de los niños. Para la prueba que propone A. Gali en el ciclo inicial, se debería realizar una revisión sobre el último grupo homogéneo, ya que se considera que aún resulta difícil para los niños de esa edad.ES
Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development
No full textDrugs derived from natural products, particularly from plants, are the leads of clinically used anticancer agents. Plant-derived anticancer agents in clinical use consist of the Vinca alkaloids, vinblastine and vincristine, camptothecin derivatives, paclitaxel, etoposide and teniposide, homoharringtonine and elliptinium. Extensive research has led to the identification of promising plant-derived anticancer agents in clinical development, namely flavopiridol, combretastatins and roscovitine. These compounds share common antitumor activities and signaling pathways targeting tumor cell cycle and cell death. This review presents the discovery of plant-derived anticancer agents, their biologic activities, with emphasis on cell cycle and apoptotic effects and combination strategies for treatment optimization. © 2007 Informa UK Ltd.Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074-jbc.M005267200; Advani Ranjana, 2006, J Natl Compr Canc Netw, V4, P241; Aggarwal BB, 2004, EXPERT OPIN INV DRUG, V13, P1327, DOI 10.1517-13543784.13.10.1327; Albihn A, 2006, J CELL BIOCHEM, V98, P1597, DOI 10.1002-jcb.20816; Alonso M, 2003, MOL CANCER THER, V2, P139; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182-blood-2004-07-2713; ARMSTRON.JG, 1967, CANCER RES, V27, P221; Atanasova G, 2005, BIOCHEM PHARMACOL, V70, P824, DOI 10.1016-j.bcp.2005.06.005; AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1, DOI 10.1016-0003-9861(87)90463-2; BAASKE DM, 1977, ANTIMICROB AGENTS CH, V12, P298; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074-jbc.M500806200; Baldwin E. L., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P363, DOI 10.2174-1568011054222364; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016-j.lfs.2005.09.012; Bennouna J, 2005, EXPERT OPIN INV DRUG, V14, P1259, DOI 10.1517-13543784.14.10.1259; Bergeron S, 2004, MOL CANCER THER, V3, P1659; Bhutani Manisha, 2006, Indian J Chest Dis Allied Sci, V48, P49; Blagosklonny Mikhail V, 2002, Cell Cycle, V1, P375; Blagosklonny MV, 2005, CELL CYCLE, V4, P269; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161-cc.3.12.1278; Borgne A, 2006, ONCOGENE, V25, P7361, DOI 10.1038-sj.onc.1209718; BROOKS DJ, 1996, SEMIN ONCOL S, V23, pS30; Cai Z, 2001, LEUKEMIA, V15, P567; Cai Z, 2005, CHINESE MED J-PEKING, V118, P548; Carlson BA, 1996, CANCER RES, V56, P2973; CASTOR TP, 2006, MASS HIGH TECH, V22, P1; Ceruti S, 2006, J PHARMACOL EXP THER, V319, P1424, DOI 10.1124-jpet.106.109397; Chang BD, 1999, CANCER RES, V59, P3761; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016-S1074-5521(99)80048-9; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074-jbc.M102306200; Chiu CC, 2005, CANCER LETT, V223, P249, DOI 10.1016-j.canlet.2004.10.049; Ciusani E, 2005, J NEURO-ONCOL, V71, P19, DOI 10.1007-s11060-004-9180-4; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038-nature03194; Clegg A, 2001, Health Technol Assess, V5, P1; Conroy T, 2002, CRIT REV ONCOL HEMAT, V42, P173, DOI 10.1016-S1040-8428(01)00180-9; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016-j.jep.2005.05.011; Crescenzi E, 2005, CLIN CANCER RES, V11, P8158, DOI 10.1158-1078-0432; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016-S0140-6736(00)02074-2; Dark GG, 1997, CANCER RES, V57, P1829; Dasmahapatra G, 2006, MOL PHARMACOL, V69, P288, DOI 10.1124-mol.105.016154; Day TW, 2006, BIOCHEM PHARMACOL, V71, P1551, DOI 10.1016-j.bcp.2006.02.015; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158-0008-5472.CAN-04-0204; DENEKAMP J, 1982, BRIT J CANCER, V45, P136, DOI 10.1038-bjc.1982.16; Dickson M, 2004, NAT REV DRUG DISCOV, V3, P417, DOI 10.1038-nrd1382; Duflos Alain, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P55, DOI 10.2174-1568011023354452; Ehrlichova M, 2005, ANTICANCER RES, V25, P4215; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158-0008-5472.CAN-04-4095; Etievant C, 2001, CANCER CHEMOTH PHARM, V48, P62, DOI 10.1007-s002800100275; Fan MY, 2000, CANCER RES, V60, P6403; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074-jbc.M411890200; FRESNO M, 1977, EUR J BIOCHEM, V72, P323, DOI 10.1111-j.1432-1033.1977.tb11256.x; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998; Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016-j.ctrv.2006.07.001; Gali-Muhtasib H, 2002, CURR CANCER DRUG TAR, V2, P309, DOI 10.2174-1568009023333809; Garcia-Manero G, 2002, INTERNAL MED, V41, P254, DOI 10.2169-internalmedicine.41.254; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073-pnas.132275599; Giovannetti E, 2005, BRIT J CANCER, V92, P681, DOI 10.1038-sj.bjc.6602382; Glaberman Ursa, 2005, Expert Opin Drug Deliv, V2, P323, DOI 10.1517-17425247.2.2.323; Glaser T, 2001, BIOCHEM BIOPH RES CO, V281, P322, DOI 10.1006-bbrc.2001.4349; Gommersall LM, 2005, NAT CLIN PRACT ONCOL, V2, P298, DOI 10.1038-ncponc0196; GOODWIN S, 1959, J AM CHEM SOC, V81, P1903, DOI 10.1021-ja01517a031; Grant S, 2003, DRUG RESIST UPDATE, V6, P15, DOI 10.1016-S1368-7646(02)00141-3; Greenberg VL, 2005, ONCOGENE, V24, P4851, DOI 10.1038-sj.onc.1208624; Grivicich I, 2005, ONCOL RES, V15, P385; Groninger E, 2002, INT J ONCOL, V21, P1339; Hagg M, 2004, MOL CANCER THER, V3, P489; Hartmann JT, 2006, DRUG SAFETY, V29, P209, DOI 10.2165-00002018-200629030-00005; Hartwell JL, 1982, PLANTS USED CANC; Hassan MAIA, 2006, CANCER GENE THER, V13, P1105, DOI 10.1038-sj.cgt.7700984; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038-sj-onc.1206409; Henfling MER, 2004, INT J ONCOL, V25, P1437; Henley D, 2007, CANCER CHEMOTH PHARM, V59, P235, DOI 10.1007-s00280-006-0262-1; Holwell SE, 2001, BRIT J CANCER, V84, P290, DOI 10.1054-bjoc.2000.1587; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; HUANG MT, 1975, MOL PHARMACOL, V11, P511; Islaih M, 2005, MUTAT RES-FUND MOL M, V578, P100, DOI 10.1016-j.mrfmmm.2005.04.012; Iyer S, 1998, CANCER RES, V58, P4510; Jean-Decoster C, 1999, ANTI-CANCER DRUG, V10, P537, DOI 10.1097-00001813-199907000-00005; Jin J, 2006, LEUKEMIA, V20, P1361, DOI 10.1038-sj.leu.2404287; JOHNSON IS, 1963, CANCER RES, V23, P1390; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174-1568011023354290; Kanthou C, 2004, AM J PATHOL, V165, P1401, DOI 10.1016-S0002-9440(10)63398-6; Karp JE, 2005, CLIN CANCER RES, V11, P8403, DOI 10.1158-1078-0432.CCR-05-1201; Karpinich NO, 2006, J CELL PHYSIOL, V208, P55, DOI 10.1002-jcp.20638; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093-jnci-84.22.1736; Kawakami K, 1999, ANTICANCER RES, V19, P3927; Kelland Lloyd R, 2005, Expert Opin Emerg Drugs, V10, P413, DOI 10.1517-14728214.10.2.413; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021-jm00105a017; Kitada S, 2000, BLOOD, V96, P393; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038-nrd1657; Koizumi N, 2005, INT J ONCOL, V26, P1301; Kolfschoten GM, 2002, BIOCHEM PHARMACOL, V63, P733, DOI 10.1016-S0006-2952(01)00895-4; Kramer R, 2004, NAT REV DRUG DISCOV, V3, P965, DOI 10.1038-nrd1552; Kruczynski A, 1998, CANCER CHEMOTH PHARM, V41, P437, DOI 10.1007-s002800050764; Kumar L, 2006, NATL MED J INDIA, V19, P80; Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016-j.canlet.2004.09.046; Kuo PL, 2005, ANTI-CANCER DRUG, V16, P789, DOI 10.1097-01.cad.0000171768.36317.93; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007-s10495-005-3372-z; LAVELLE F, 1995, SEMIN ONCOL S4, V22, pS3; Lee YK, 2006, MOL CANCER THER, V5, P138, DOI 10.1158-1535-7163.MCT-05-0235; Li QY, 2006, CURR MED CHEM, V13, P2021, DOI 10.2174-092986706777585004; Litz J, 2003, CLIN CANCER RES, V9, P4586; Liu XM, 2001, BRIT J CANCER, V85, P1403, DOI 10.1054-bjoc.2001.2107; Lobert S, 1998, MOL PHARMACOL, V53, P908; LOGH BH, 1994, CANC CHEMOTHER PHA S, V34, pS26; Lu KH, 2005, CLIN CHIM ACTA, V357, P65, DOI 10.1016-j.cccn.2005.02.003; Lu KH, 2005, J ORTHOP RES, V23, P988, DOI 10.1016-j.orthres.2005.01.018; Luo Chang Ying, 2004, Hematology, V9, P259, DOI 10.1080-10245330410001714194; Lyseng-Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165-00003495-200565170-00007; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158-0008-5472.CAN-05-0233; Magalska A, 2006, INT J CANCER, V119, P1811, DOI 10.1002-ijc.22055; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021-ar0201198; Mialon A, 2005, MOL CELL BIOL, V25, P5040, DOI 10.1128-MCB.25.12.5040-5051.2005; Minderman H, 2005, MOL CANCER THER, V4, P885, DOI 10.1158-1535-7163.MCT-04-0048; Miyashita K, 2006, INT J MOL MED, V18, P249; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Navakauskiene R, 2004, ANN NY ACAD SCI, V1030, P393, DOI 10.1196-annals.1329.049; NEGORO S, 1991, J NATL CANCER I, V83, P1164, DOI 10.1093-jnci-83.16.1164; Newcomb EW, 2004, ANTI-CANCER DRUG, V15, P411, DOI 10.1097-01.cad.0000127332.06439.47; Newman DJ, 2002, CURR CANCER DRUG TAR, V2, P279, DOI 10.2174-1568009023333791; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021-np030096l; Ngan VK, 2000, CANCER RES, V60, P5045; NOBLE RL, 1958, ANN NY ACAD SCI, V76, P882, DOI 10.1111-j.1749-6632.1958.tb54906.x; Oberlies NH, 2004, J NAT PROD, V67, P129, DOI 10.1021-np030498t; O'Brien S, 2003, CANCER, V98, P888, DOI 10.1002-cncr.11620; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038-sj-cdd-4401012; OHASHI M, 1995, JPN J CANCER RES, V86, P819; Panno ML, 2006, FEBS LETT, V580, P2371, DOI 10.1016-j.febslet.2006.03.055; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074-jbc.M406543200; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038-sj.onc.1206777; Pepper Chris, 2003, Cell Cycle, V2, P53; Perez-Stable C, 2006, CANCER LETT, V231, P49, DOI 10.1016-j.canlet.2005.01.018; Pettit GR, 1982, CAN J CHEM, V60, P1347; PETTIT GR, 1987, CAN J CHEM, V65, P2390; PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299; Podwyssotzki V, 1881, PHARM J T, V12, P217; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038-nrc1977; POTIER P, 1989, SEMIN ONCOL, V16, P2; Pourroy B, 2004, MOL PHARMACOL, V66, P580; POWELL RG, 1972, J PHARM SCI, V61, P1227, DOI 10.1002-jps.2600610812; Pratt MAC, 2006, APOPTOSIS, V11, P589, DOI 10.1007-s10495-006-4603-7; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128-MCB.20.8.2629-2634.2000; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182-blood-2005-01-0320; Ramnath N, 2005, CANCER CHEMOTH PHARM, V56, P447, DOI 10.1007-s00280-004-0951-6; Reck M, 2006, LUNG CANCER, V53, P67, DOI 10.1016-j.lungcan.2006.04.001; Reichert JM, 2003, NAT REV DRUG DISCOV, V2, P695, DOI 10.1038-nrd1178; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093-jnci-83.4.288; Rodriguez-Hernandez A, 2006, APOPTOSIS, V11, P131, DOI 10.1007-s10495-005-3276-y; Rossi A, 2003, ANTICANCER RES, V23, P1657; Rossi R, 2006, CANCER RES, V66, P1675, DOI 10.1158-0008-5472.CAN-05-2741; Russo AJ, 2006, CANCER RES, V66, P7253, DOI 10.1158-0008-5472.CAN-05-3725; Sambol EB, 2006, CANCER RES, V66, P5858, DOI 10.1158-0008-5472.CAN-05-2933; Savio M, 2006, CELL CYCLE, V5, P2153, DOI 10.4161-cc.5.18.3235; Scagliotti G, 2004, LUNG CANCER-J IASLC, V46, pS13, DOI 10.1016-S0169-5002(04)80037-0; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016-S1040-8428(00)00124-4; SENDEROWICZ AM, 2002, ONCOLOGIST S, V7, pS12; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038-sj.onc.1206954; Shapiro GI, 1999, CLIN CANCER RES, V5, P2925; SINGH MP, 1994, BIOCHEMISTRY-US, V33, P10271, DOI 10.1021-bi00200a007; Smith LM, 2005, CLIN CANCER RES, V11, P8449, DOI 10.1158-1078-0432.CCR-05-1224; Stiborova Marie, 2006, Biomedical Papers (Olomouc), V150, P13; Stiborova M, 2004, CANCER RES, V64, P8374, DOI 10.1158-0008-5472.CAN-04-2202; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158-0008-5472.CAN-05-1997; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016-S0014-2999(97)01520-3; Swanton C, 2006, CELL CYCLE, V5, P818, DOI 10.4161-cc.5.8.2682; Takahashi T, 2005, MOL CANCER THER, V4, P1039, DOI 10.1158-1535-7163.MCT-04-0282; Tang RP, 2006, MOL CANCER THER, V5, P723, DOI 10.1158-1535-7163.MCT-05-0164; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158-0008-5472.CAN-03-2770; Taniguchi T, 2005, INT J MOL MED, V15, P667; Tirado OM, 2005, CANCER RES, V65, P9320, DOI 10.1158-0008-5472.CAN-05-1276; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038-nrc1628; Tron GC, 2006, J MED CHEM, V49, P3033, DOI 10.1021-jm0512903; Venkataraman G, 2006, LEUKEMIA RES, V30, P1377, DOI 10.1016-j.leukres.2006.03.004; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021-ja00968a057; Wall NR, 1999, LEUKEMIA RES, V23, P881, DOI 10.1016-S0145-2126(99)00108-3; Wall NR, 2003, CANCER RES, V63, P230; Wang Q, 2004, ONCOGENE, V23, P426, DOI 10.1038-sj.onc.1207040; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074-jbc.274.12.8208; Wang Z, 2005, ANTICANCER RES, V25, P2367; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021-ja00738a045; Wehbe H, 2005, ANTICANCER RES, V25, P3865; Wesierska-Gadek J, 2005, MOL CANCER THER, V4, P113; West CML, 2004, ANTI-CANCER DRUG, V15, P179, DOI 10.1097-01.CAD.0000119456.84063.82; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158-0008-5472.CAN-03-0110; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016-0006-2952(93)90590-S; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158-1535-7163.MCT-06-0077; Xie WZ, 2006, AM J CHINESE MED, V34, P233, DOI 10.1142-S0192415X06003795; XU B, 1981, AM J CHINESE MED, V9, P268, DOI 10.1142-S0192415X81000354; Yinjun Lou, 2004, Am J Hematol, V76, P199, DOI 10.1002-ajh.20100; You YJ, 2005, CURR PHARM DESIGN, V11, P1695, DOI 10.2174-1381612053764724; Young SL, 2004, EXPERT OPIN INV DRUG, V13, P1171, DOI 10.1517-13543784.13.9.1171; Yu CR, 2003, CANCER RES, V63, P1822; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038-sj.onc.1209202; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174-1568009033333754; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038-sj.cgt.7700910; Zhao JS, 2005, INT J ONCOL, V27, P24756
Radiosensitization of EMT6 mammary carcinoma cells by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide
No full textBackground and purpose: Previously, we have reported that 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide (DCQ) is a radiosensitizer. Here, we investigate the mechanism of radiosensitization. Materials and methods: EMT6 cells were treated with DCQ for 4 h prior to ionizing radiation (IR). Flow cytometry, clonogenic assay, TUNEL, and Western blotting were performed to assess the effect of treatment on cells. Results: Propidium iodide staining of EMT6 cells treated with IR ± DCQ revealed high numbers of cells with decreased DNA, consistent with an apoptotic response. TUNEL assay revealed apoptosis was 4percent, 38percent, and 49percent 24 h after treatment with IR alone, DCQ alone, and DCQ + IR, respectively. Clonogenic assays revealed that the survival of irradiated EMT6 cells was significantly reduced by DCQ treatment. DCQ treatment abrogated the radiation-induced expression of p21 and p53. The increased apoptosis observed in DCQ + IR-treated cells was correlated to suppression of radiation-induced phosphorylation of Akt and the expression of Bcl-XL. DCQ also caused the phosphorylation of mitogen-activated protein kinases Erk and Jnk. Conclusions: The radiosensitization effect of DCQ occurs through enhancement of radiation-induced apoptosis, which correlates to the inhibition of p-Akt kinase and Bcl-XL and the activation of Erk and Jnk kinases, but appears independent of p53 induction or modulation of Bax-Bcl-2 gene expression. These data suggest DCQ should be tested as a radiosensitizer in vivo and has potential in the treatment of human solid tumors. © 2008.Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126-science.281.5381.1322; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073-pnas.96.3.1002; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126-science.296.5573.1655; Chiosis G, 2001, BIOORG MED CHEM LETT, V11, P909, DOI 10.1016-S0960-894X(01)00099-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038-nrc883; Dangi S, 2003, CELL SIGNAL, V15, P667, DOI 10.1016-S0898-6568(03)00002-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101-gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042-0264-6021:3510095; DIABASSAF M, 2000, MOL CARCINOG, V33, P198; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126-science.281.5381.1317; Figueroa C, 2003, J BIOL CHEM, V278, P47922, DOI 10.1074-jbc.M307357200; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016-S0167-4889(00)00018-5; Gali-Muhtasib H, 2004, INT J ONCOL, V24, P1121; Gali-Muhtasib HU, 2005, CANCER CHEMOTH PHARM, V55, P369, DOI 10.1007-s00280-004-0907-x; Gali-Muhtasib HU, 2001, ONCOL REP, V8, P679; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038-sj-onc-1205181; Gottschalk AR, 2005, INT J RADIAT ONCOL, V63, P1221, DOI 10.1016-j.ijrobp.2005.08.014; Gupta AK, 2001, CANCER RES, V61, P4278; HADDADIN MJ, 1993, HETEROCYCLES, V35, P1503; Harakeh S, 2004, CHEM-BIOL INTERACT, V148, P101, DOI 10.1016-j.cbi.2004.05.002; Itani W., 2007, RAD ONCOL, V2; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128-MCB.22.22.7831-7841.2002; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016-S0896-6273(02)00821-8; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126-science.275.5303.1132; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038-sj.onc.1204942; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016-S0092-8674(00)81871-1; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174-1568026023393318; Liang K, 2003, MOL CANCER THER, V2, P1113; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038-35003670; Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038-sj.onc.1201585; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038-sj.onc.1203597; McKenna WG, 2003, ONCOGENE, V22, P5866, DOI 10.1038-sj.onc.1206699; Nakamura JL, 2005, J NEURO-ONCOL, V71, P215, DOI 10.1007-s11060-004-1718-y; POWIS G, 1994, CANCER RES, V54, P2419; Price BD, 1996, CANCER RES, V56, P246; Riesterer O, 2004, INT J RADIAT ONCOL, V58, P361, DOI 10.1016-j.ijrobp.2003.09.050; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038-5042; Shonai T, 2002, CELL DEATH DIFFER, V9, P963, DOI 10.1038-sj.cdd.4401050; Soderlund K, 2005, INT J ONCOL, V26, P25; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074-jbc.M111598200; Tenzer A, 2001, CANCER RES, V61, P8203; Watanabe H, 2004, INT J RADIAT BIOL, V80, P451, DOI 10.1080-09553000410001702355; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016-S1368-7646(02)00120-6; Yang J, 2003, MUTAT RES-REV MUTAT, V543, P31, DOI 10.1016-S1383-5742(02)00069-8; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126-science.7701324; Zhan M, 2004, HISTOL HISTOPATHOL, V19, P915; Zhang L, 2003, CANCER RES, V63, P422569
- …
